Scientists create a 'sense' DNA drug that can undo the effects of an antisense drug used to treat blood clots. The new approach reversed the antisense drug's activity and restored normal levels of prothrombin, preventing bleeding. This breakthrough demonstrates the feasibility of using oligonucleotides to target specific genes.
SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalNucleic Acid Therapeutics·DateOct 13, 2015
Researchers at Tokyo Medical and Dental University developed a novel DNA/RNA heteroduplex oligonucleotide (HDO) that significantly improves gene silencing and reduces liver dysfunction. The high potency of vitamin E-conjugated HDO results in improved delivery to the liver, leading to enhanced therapeutic effects.
SourceTokyo Medical and Dental University·JournalNature Communications·DateAug 12, 2015
MGN1703 is a single-stranded oligonucleotide-based drug that activates the human immune system without causing harmful side effects. It works by binding to toll-like receptor 9, triggering a cascade of signaling pathways that enable recognition and destruction of foreign cells.
SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalNucleic Acid Therapeutics·DateApr 7, 2015
Researchers have developed nanoparticles that can efficiently transport charge-neutral oligonucleotide analogs into cells, enabling them to retain biological activity. This breakthrough delivery approach has the potential to treat various therapeutic targets.
SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalNucleic Acid Therapeutics·DateJan 27, 2015
DJI Air 3 (RC-N2)
DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.
The review article explores the therapeutic advantages of phosphorothioate groups in oligonucleotides, enabling novel gene expression-regulation therapies. Novel applications include microRNA and long non-coding RNA targets and decoy oligonucleotides.
SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalNucleic Acid Therapeutics·DateNov 13, 2014
The article presents new consensus guidelines for toxicity testing of oligonucleotide drugs, considering their unique chemical and biological characteristics. The guidelines aim to design scientifically valid and predictive toxicity studies.
SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalNucleic Acid Therapeutics·DateOct 30, 2014
A novel RNAi-based therapy has shown promising results in treating anemia by stimulating the liver to produce erythropoietin (EPO). The treatment targets the EGLN1 gene, leading to increased EPO and hemoglobin levels. This breakthrough could provide a safer alternative to current recombinant human EPO treatments.
SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalNucleic Acid Therapeutics·DateOct 16, 2014
Fluke 87V Industrial Digital Multimeter
Fluke 87V Industrial Digital Multimeter is a trusted meter for precise measurements during instrument integration, repairs, and field diagnostics.
Researchers have developed a promising new approach to editing gene transcripts, which uses targeted oligonucleotide drugs. This technique has already shown promise in treating diseases such as Duchenne Muscular Dystrophy and spinal muscular atrophy.
SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalHuman Gene Therapy·DateJul 17, 2014
A group of industry and regulatory scientists released consensus recommendations for assessing the safety pharmacology evaluations of oligonucleotide-based therapeutics. The guidelines emphasize the importance of safety pharmacology studies to evaluate cardiovascular function effects.
SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalNucleic Acid Therapeutics·DateJul 8, 2014
Researchers use antisense oligonucleotides to skip over the mutated exon causing Huntington's disease, preventing formation of toxic protein fragments. The innovative therapeutic strategy is a proof-of-concept for treating complex diseases.
SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalNucleic Acid Therapeutics·DateFeb 11, 2014
SAMSUNG T9 Portable SSD 2TB
SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.
A new study demonstrates the effectiveness of antisense drugs in targeting a wide range of tissues and organs, including liver, kidney, lung, muscle, and peripheral nerves. The findings suggest that antisense therapeutics have broad therapeutic potential for various disease indications.
SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalNucleic Acid Therapeutics·DateDec 10, 2013
A novel machine learning-based approach predicts hepatotoxic potential of antisense oligonucleotides based on chemical sequence. The method achieved 74% accuracy in predicting toxicity and was used to redesign a therapeutic oligonucleotide with reduced potential for liver harm.
SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalNucleic Acid Therapeutics·DateAug 27, 2013
Researchers have identified key regions in the dengue virus genome that can be targeted to prevent replication. Artificial microRNAs were constructed to specifically target these sites, leading to effective inhibition of viral replication in humans. This innovative approach offers new hope for treating millions affected by dengue fever.
SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalNucleic Acid Therapeutics·DateJul 11, 2013
A new method for manufacturing short, single-stranded DNA molecules has been developed by researchers at Karolinska Institutet and Harvard University. This technique can produce large amounts of DNA copies cheaply using bacteria, improving the quality and scalability of DNA fragment production.
SourceKarolinska Institutet·JournalNature Methods·DateJun 2, 2013
Apple iPhone 17 Pro
Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.
Gene Signal's aganirsen shows promise in treating wet age-related macular degeneration and ischemic retinopathy by inhibiting neovascular growth. Clinical studies are scheduled to begin during the second quarter of 2012.
Myotonic dystrophy is caused by a mutation that causes toxic RNA to accumulate in cells. Antisense oligonucleotides have been shown to be effective in cell culture and mice by degrading the toxic RNA. The treatment will need to be refined for systemic delivery to patients with myotonic dystrophy.
SourceBaylor College of Medicine·JournalProceedings of the National Academy of Sciences·DateFeb 27, 2012
A new DNA testing method, MEMO, has been developed to detect trace mutant DNA sequences with improved sensitivity. The technique uses 3′-modified oligonucleotides to block normal gene extension while allowing mutated gene extension, increasing detection sensitivity.
SourceElsevier Health Sciences·JournalJournal of Molecular Diagnostics·DateOct 11, 2011
CalDigit TS4 Thunderbolt 4 Dock
CalDigit TS4 Thunderbolt 4 Dock simplifies serious desks with 18 ports for high-speed storage, monitors, and instruments across Mac and PC setups.
Antigene therapy utilizes a DNA-based drug that attaches directly to specific DNA sequences and is activated by light energy, effectively silencing targeted genes. This approach may offer new hope for treating diseases currently incurable or having limited success.
SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalOligonucleotides·DateOct 21, 2010
Researchers developed DNA-like compounds that effectively inhibit cells responsible for systemic lupus erythematosus, a potentially groundbreaking treatment. The findings demonstrate the anti-inflammatory effects of class R inhibitory oligonucleotides and could lead to new therapies.
SourceUniversity of Iowa·JournalArthritis Research & Therapy·DateMay 27, 2009
The development of siRNA drugs is hindered by a strong immune response that can cause toxic side effects. Researchers are exploring mechanisms for inducing this response and strategies for minimizing its effects.
SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalOligonucleotides·DateMay 20, 2009
Davis Instruments Vantage Pro2 Weather Station
Davis Instruments Vantage Pro2 Weather Station offers research-grade local weather data for networked stations, campuses, and community observatories.
Researchers delivered antisense oligonucleotides through cerebrospinal fluid to treat neurodegenerative diseases like ALS. The therapy effectively modulated protein levels and slowed disease progression in rats.
SourceJCI Journals·JournalJournal of Clinical Investigation·DateJul 27, 2006
Researchers found that glucocorticoids (GCs) alter the activity of bone-forming and bone-degrading cells, leading to delayed bone formation and resulting in GC-induced osteoporosis. Antisense oligonucleotides can be delivered through cerebrospinal fluid to treat neurodegenerative diseases like ALS.
SourceJCI Journals·JournalJournal of Clinical Investigation·DateJul 27, 2006
Researchers develop system to study small RNAs using siRNA inhibitors, providing unprecedented insight into RNA interference and microRNA functions. The technique enables rapid discovery of hundreds of microRNAs' regulatory roles, with significant implications for genetic studies.
Researchers at UNC used antisense oligonucleotides to target RNA splicing pathways implicated in cancer and genetic diseases. The technique successfully sensitized cancer cells to chemotherapy and radiation, offering a potential breakthrough for targeted therapy.
SourceUniversity of North Carolina Health Care·JournalJournal of Biological Chemistry·DateJan 8, 2003